drugset / Trial / NCT05708859
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RandomizedParallel-groupQuadruple-blindHealth-services research
Summary
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
Timeline
- Start
- 2024-01-02
- Primary completion
- 2025-12
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tirzepatide | Peptide | 15 mg | Subcutaneous |